‘retatrutide’ directory
- See Also
- Links
- “The Power of Three: Retatrutide’s Role in Modern Obesity and Diabetes Therapy ”, Abdul-Rahman et al 2024
- “‘Skinny Jabs’: Weight-Loss Drugs Set for New Boom As Generic Liraglutide Versions Emerge ”, Davis & Kollewe 2024
- “Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease: a Randomized Phase 2a Trial ”, Sanyal et al 2024
- “A Revolution in Obesity Treatment ”, Lingvay & Agarwal 2023
- “Goodbye, Ozempic: A New Class of Drugs Is Transforming Obesity Care. They Are Not All the Same ”, Engber 2023
- “Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial: Supplement ”, Jastreboff 2023
- “Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial ”, Jastreboff et al 2023
- “Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People With Type 2 Diabetes: a Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial Conducted in the USA ”, Rosenstock et al 2023
- xKloc @ "2022-12-13"
- “Retatrutide, a Novel Triple GIP, GLP-1, and Glucagon Receptor Agonist in People With Type 2 Diabetes: a Phase 1b, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Multiple-Ascending Dose Trial ”, Urva et al 2022
- “LY3437943, a Novel Triple Glucagon, GIP, and GLP-1 Receptor Agonist for Glycemic Control and Weight Loss: From Discovery to Clinical Proof of Concept ”, Coskun et al 2022
- Wikipedia (3)
- Miscellaneous
- Bibliography
See Also
Links
“The Power of Three: Retatrutide’s Role in Modern Obesity and Diabetes Therapy ”, Abdul-Rahman et al 2024
The power of three: Retatrutide’s role in modern obesity and diabetes therapy :
“‘Skinny Jabs’: Weight-Loss Drugs Set for New Boom As Generic Liraglutide Versions Emerge ”, Davis & Kollewe 2024
‘Skinny jabs’: weight-loss drugs set for new boom as generic liraglutide versions emerge
“Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease: a Randomized Phase 2a Trial ”, Sanyal et al 2024
“A Revolution in Obesity Treatment ”, Lingvay & Agarwal 2023
“Goodbye, Ozempic: A New Class of Drugs Is Transforming Obesity Care. They Are Not All the Same ”, Engber 2023
Goodbye, Ozempic: A new class of drugs is transforming obesity care. They are not all the same
“Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial: Supplement ”, Jastreboff 2023
Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial: Supplement :
“Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial ”, Jastreboff et al 2023
Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial
“Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People With Type 2 Diabetes: a Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial Conducted in the USA ”, Rosenstock et al 2023
xKloc @ "2022-12-13"
“Retatrutide, a Novel Triple GIP, GLP-1, and Glucagon Receptor Agonist in People With Type 2 Diabetes: a Phase 1b, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Multiple-Ascending Dose Trial ”, Urva et al 2022
“LY3437943, a Novel Triple Glucagon, GIP, and GLP-1 Receptor Agonist for Glycemic Control and Weight Loss: From Discovery to Clinical Proof of Concept ”, Coskun et al 2022
Wikipedia (3)
Miscellaneous
Bibliography
https://www.theguardian.com/business/article/2024/jun/25/skinny-jabs-weight-loss-drugs-generic-ozempic-wegovy-saxenda: “‘Skinny Jabs’: Weight-Loss Drugs Set for New Boom As Generic Liraglutide Versions Emerge ”,2023-lingvay.pdf: “A Revolution in Obesity Treatment ”,https://www.theatlantic.com/health/archive/2023/06/ozempic-pills-obesity-drugs-semaglutide/674541/: “Goodbye, Ozempic: A New Class of Drugs Is Transforming Obesity Care. They Are Not All the Same ”,